• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eddie Sullivan named to BIO executive committee

Eddie Sullivan named to BIO executive committee

June 30, 2016
CenterWatch Staff

South Dakota Biotech leader Eddie Sullivan has been named to the executive committee of the Biotechnology Innovation Organization, or BIO, the industry’s largest trade association.

Sullivan, president and CEO of SAB Biotherapeutics (SAB), was named the chair of the organization's food and agriculture section governing board. He has been a member of that board since 2004.

"As we address the numerous challenges of feeding a growing world, it’s by the industry coming together through a broad and the prestigious organization BIO that we're able to leverage biotechnology to benefit society—in particular the lower and middle income countries,” Sullivan said.

Sullivan is the founder and former board chair of South Dakota Biotech, the state’s affiliate of BIO, now in its 10th year.

“Eddie is a valuable asset to South Dakota and has been a visionary for our industry,” said Joni Johnson, South Dakota Biotech executive director. “It’s a tremendous opportunity to have him assume this important leadership role within the BIO organization.”

Sullivan is now part of an 18-person executive committee for the BIO board. As chair of the food and agriculture section, he helps oversee the creation and advancement of policies and issues related to international affairs, government relations, science and regulatory affairs, and media and public affairs. He was appointed at the recent international BIO conference in San Francisco.

“We welcome our new officers, board leaders, and board members, and are looking forward to working with them to create a more favorable policy, legislative, and business development environment for the global biotech industry,” said Jim Greenwood, BIO president and CEO. “This newly-constituted board of directors brings significant industry experience and passion that will serve BIO and its members well.”

“We are pleased to announce Eddie Sullivan, president and CEO of SAB Biotherapeutics, as the new chair of the Food and Agriculture Section Governing Board. Throughout his tenure as a valued BIO member and during his previous two-year term as vice chair, we have relied on Dr. Sullivan’s expertise in science, policy and business development,” said Brian Baenig, executive vice president for Food and Agriculture at BIO. “We look forward to working more closely with him on the challenges facing not just ag biotech, but the global biotechnology industry as a whole.”

As a seasoned biotechnology executive, Sullivan has more than 15 years of leadership experience with genetic and molecular diagnostics for animal health. He has also co-founded multiple biotech development companies. His current company, SAB Biotherapeutics, is a biopharmaceutical company developing polyclonal antibody therapies to treat infectious diseases, cancer and autoimmune disorders.

“Although SAB is developing human therapeutics, they are produced in agriculture-related species,” Sullivan said. “Therefore, we work very closely with the USDA, FDA and other regulatory organizations that are covered by the Food and Ag section of BIO.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing